NLR family CARD domain containing 3Genealiases: CLR16.2 · NOD3
Q-omics provides the consensus-scored NLRC3 profile across patient tissues and cancer cell-line models. NLRC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NLRC3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NLRC3 RNA expression shows 19,634 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where NLRC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRC3 survival associations across molecular data types. NLRC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRC3 RNA expression–survival associations across cancer types. High NLRC3 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, UCEC, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NLRC3 RNA expression.
This table summarizes NLRC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NLRC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRC3 shows lower tumor expression in LUSC, KICH, UCEC and COAD and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher NLRC3 RNA expression in tumor versus normal tissue (log2 FC = +1.017, t-test p < 0.001).
This table shows molecular features associated with NLRC3 in patient tissues and cancer cell lines. In patient samples, NLRC3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and OESOPHAGUS.
